Amarin Corp. PLC doesn’t want its icosapent ethyl drug called a “fish oil product” now that it has approval for an additional cardiovascular risk indication that further differentiates it from fish oil dietary ingredients it contends are unfair competition.
The US Food and Drug Administration on 13 December approved Vascepa as an add-on to statin therapy to help cut...





